Traws Pharma reported a net loss of $3.0 million, or $0.16 per share, for the quarter ended June 30, 2026, compared to a $0.9 million loss in the prior year period. The company held $5.0 million in cash and cash equivalents as of June 30, 2026. Traws is advancing its lead candidate, tivoxavir marboxil, toward an MHRA resubmission for a Phase 2a human influenza Challenge study by the end of Q3 2026, while working to resolve an FDA clinical hold in the U.S. The company completed a private placement in April 2026 that delivered $10.0 million in upfront proceeds and secured shareholder approval for Series B and C warrant tranches, enabling access to up to $50.0 million in additional milestone-based financing. Traws Pharma is a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases.

Traws Pharma, Inc. received a notification from Nasdaq on July 29, 2026, indicating non-compliance with the Minimum Bid Price Requirement because its common stock closed below $1.00 per share for at least 30 consecutive business days. The listing remains effective as the company has until January 25, 2027, to regain compliance by maintaining a closing price of at least $1.00 for ten consecutive business days. Failure to comply may result in delisting proceedings. Traws Pharma operates in the biopharmaceutical industry, focusing on drug discovery and development.

Traws Pharma, Inc. filed a prospectus supplement dated July 10, 2026, to its effective shelf registration statement, enabling the company to offer and sell common stock with an aggregate offering price of up to $5,575,709 through its existing At The Market (ATM) offering agreement with Citizens JMP Securities, LLC. This sale is subject to ability to use its current "baby shelf

At its 2026 Annual Meeting of Stockholders held on July 8, 2026, Traws Pharma, Inc. stockholders approved an amendment to the company's 2021 Incentive Compensation Plan to increase the available common stock for issuance by 2,000,000 shares. Additionally, shareholders approved the issuance of common stock upon the exercise of Series B and Series C Warrants issued to certain investors under an April 15, 2026, Securities Purchase Agreement, in compliance with Nasdaq listing rules. The meeting also resulted in the election of seven directors and the ratification of KPMG LLP as the independent registered public accounting firm for the 2026 fiscal year. Traws Pharma, Inc. is a pharmaceutical company.